Baneocin ointment d / nar. approx. tube 5g

Release form

Ointment for external use is yellowish, homogeneous, with a weak characteristic odor.

pharmachologic effect

Combined antibacterial drug for external use.

Contains two antibiotics that have a bactericidal effect, neomycin and bacitracin.

Bacitracin is a polypeptide antibiotic that inhibits the synthesis of the bacterial cell wall.

Active against gram-positive (Streptococcus spp. / Including? -Hemolytic streptococcus /, Staphylococcus spp.) And some gram-negative microorganisms.

Resistance to bacitracin is rare.

Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis.

Active against gram-positive and gram-negative bacteria.

Through the use of a combination of these two antibiotics, a wide spectrum of action of the drug and synergism of action against a number of microorganisms, for example, staphylococci, are achieved.

Indications

Treatment of infectious and inflammatory skin diseases caused by microorganisms sensitive to the drug:

- focal skin infections, incl.

boils, carbuncles (after surgery), staphylococcal sycosis, periporitis, deep folliculitis, purulent hydradenitis, paronychia

- bacterial skin infections of limited prevalence, incl.

contagious impetigo, infected ulcers of the lower extremities, secondarily infected eczema, secondary infection with dermatoses, cuts, abrasions, burns, cosmetic surgery and skin transplantation (also for prophylaxis and for dressing dressings).

Prevention and treatment of infection after surgery (as part of combination therapy in the postoperative period).

Contraindications

- extensive skin lesions (the risk of developing an ototoxic effect, accompanied by hearing loss)

- severe disorders of renal excretory function (due to heart or renal failure) in patients with existing diseases of the cochleo-vestibular apparatus (if systemic absorption of the drug is possible)

- infections of the external auditory canal with perforation of the tympanic membrane

- simultaneous use with antibiotics of the aminoglycoside group of systemic action (risk of cumulative toxicity)

- hypersensitivity to bacitracin, neomycin or to other aminoglycosides, auxiliary components of the drug.

Do not use this medicine to treat eye infections.

The drug should be prescribed with caution in patients with impaired liver and / or kidney function, acidosis, severe myasthenia gravis or other neuromuscular diseases.

Application during pregnancy and lactation

The use of the drug Baneocin during pregnancy and lactation is possible after consulting a doctor and only if the intended benefit to the mother outweighs the potential risk to the fetus or infant.

It should be remembered that neomycin, like all antibiotics of the aminoglycoside group, can penetrate the placental barrier.

With the systemic use of antibiotics of the aminoglycoside group in high doses, intrauterine fetal hearing loss has been described.

special instructions

Since the risk of toxic effects increases with a decrease in liver and / or kidney function, in patients with hepatic and / or renal insufficiency, blood and urine tests should be performed along with an audiometric study before and during therapy with Baneocin.

With the possible absorption of the active components of the drug Baneocin, it is necessary to monitor for possible signs of neuromuscular blockade, especially in patients with acidosis, myasthenia gravis or other neuromuscular diseases.

With the development of neuromuscular blockade, calcium supplements or neostigmine are indicated.

With prolonged use of the drug, it is necessary to monitor the possible excessive

Name ENG

BANEOCIN

Clinical and pharmacological group

Drug with antibacterial action for external use

ATX code

Other antibiotics for external use

Dosage

250IU / g + 5000IU / g x 5g

Structure

1 g: bacitracin (in the form of bacitracin zinc) 250 IU

neomycin (in the form of neomycin sulfate) 5000 IU, excipients: lanolin, white soft paraffin.

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

INN / Active ingredient

bacitracin, neomycin

Specifications

Scope of the drug

Leather

Release form

Ointment

Manufacturer country

Austria

Package quantity, pcs

one

Way of introduction

Outwardly

,

On the skin

,

Locally

Vacation conditions

Without recipe

Brand name

Sandoz

The amount of the dosage form in the primary package

5 g

Primary packaging type

Tuba

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Combined antibiotic

Dosage form

Ointment for external use

Expiration date in days

1095

The target audience

Children

Package weight, g

ten

Category

:

Antibiotics

,

Antiseptics and disinfectants

,

Disinfectants

Mode of application

:

The drug is used externally. For adults and children, the ointment is applied in a thin layer to the affected areas - 2-3 times / day. It is possible to apply an ointment under the bandage. < br> < br> The area of ​​application of the ointment should not exceed 1% of the body surface area (which corresponds to the size of the patient's palm). < br> < br> The dose of neomycin for adults and children and adolescents under the age of 18 should not exceed 1 g / day (corresponds to 200 g of ointment) for 7 days. < br> < br> Patients with impaired liver / kidney function and elderly patients do not need dose adjustment. < br> < br> The ointment can be used as an additional treatment in the postoperative period. Application of ointment to bandages is preferred for topical treatment of infected cavities and wounds (for example,bacterial infections of the external ear canal without perforation of the tympanic membrane, wounds or surgical incisions that heal by secondary intention).

Anatomical and therapeutic characteristics

:

D06AX Other topical antibacterials

Dosage (volume) of the substance in the preparation

:

1 g: bacitracin (in the form of bacitracin zinc) 250 IU

neomycin (as neomycin sulfate) 5000 IU

Information on technical characteristics, delivery set, country of manufacture